Search research articles
Contact Us
Filters
Showing results (181-190 of 327) with videos related to
Page
of 33
Sort By:
Journal of the American Heart Association
|
November 26, 2025
Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer
Giselle Alexandra Suero-Abreu, Zsofia D Drobni, Carlos A Gongora, et al.
Oncoimmunology
|
May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
Meghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Cell
|
July 1, 2020
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M Luoma, Shengbao Suo, Hannah L Williams, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2025
Tumor location as a risk factor for severe immune-related adverse events
Steven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Science Advances
|
November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
Alvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Ryan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
JAMA Network Open
|
August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
Rachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
The Lancet. Oncology
|
June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.
The Oncologist
|
September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
NPJ Precision Oncology
|
March 2, 2023
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Douglas B Fox, Richard Y Ebright, Xin Hong, et al.
Page
of 33
Search research articles
Search
Showing results (181-190 of 327) with videos related to
Sort By:
Page
of 33
Journal of the American Heart Association
|
November 26, 2025
Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer
Giselle Alexandra Suero-Abreu, Zsofia D Drobni, Carlos A Gongora, et al.
Oncoimmunology
|
May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
Meghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Cell
|
July 1, 2020
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M Luoma, Shengbao Suo, Hannah L Williams, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2025
Tumor location as a risk factor for severe immune-related adverse events
Steven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Science Advances
|
November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
Alvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Journal for Immunotherapy of Cancer
|
June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Ryan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
JAMA Network Open
|
August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
Rachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
The Lancet. Oncology
|
June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.
The Oncologist
|
September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
NPJ Precision Oncology
|
March 2, 2023
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Douglas B Fox, Richard Y Ebright, Xin Hong, et al.
Page
of 33